Guardian Capital LP Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Guardian Capital LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 0.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,142 shares of the company’s stock after buying an additional 292 shares during the quarter. Guardian Capital LP’s holdings in AstraZeneca were worth $2,398,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Harvest Volatility Management LLC purchased a new position in AstraZeneca in the first quarter valued at $2,303,000. 1832 Asset Management L.P. increased its holdings in AstraZeneca by 239.6% in the first quarter. 1832 Asset Management L.P. now owns 3,033,929 shares of the company’s stock valued at $198,533,000 after buying an additional 2,140,670 shares during the last quarter. Captrust Financial Advisors increased its holdings in AstraZeneca by 13.0% in the first quarter. Captrust Financial Advisors now owns 60,353 shares of the company’s stock valued at $4,004,000 after buying an additional 6,954 shares during the last quarter. Brinker Capital Investments LLC increased its holdings in AstraZeneca by 27.0% in the first quarter. Brinker Capital Investments LLC now owns 98,854 shares of the company’s stock valued at $6,558,000 after buying an additional 21,026 shares during the last quarter. Finally, Wetherby Asset Management Inc. increased its holdings in AstraZeneca by 5.2% in the first quarter. Wetherby Asset Management Inc. now owns 59,446 shares of the company’s stock valued at $3,944,000 after buying an additional 2,939 shares during the last quarter. Hedge funds and other institutional investors own 21.55% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN opened at $61.75 on Tuesday. AstraZeneca PLC has a fifty-two week low of $53.63 and a fifty-two week high of $71.70. The company has a market capitalization of $191.35 billion, a price-to-earnings ratio of -150.61, a price-to-earnings-growth ratio of 1.17 and a beta of 0.44. The firm has a 50-day simple moving average of $65.24 and a 200-day simple moving average of $65.19. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.67 and a current ratio of 0.96.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were given a $0.465 dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 2.2%. AstraZeneca’s payout ratio is currently -221.95%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on AZN shares. Argus raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Monday, August 29th. AlphaValue raised AstraZeneca to a “reduce” rating in a report on Monday, August 22nd. Morgan Stanley lowered AstraZeneca from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 7th. UBS Group lowered AstraZeneca from a “buy” rating to a “neutral” rating in a report on Tuesday, June 14th. Finally, Danske started coverage on AstraZeneca in a report on Tuesday, May 24th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Hold” and an average target price of $8,840.50.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.